Phase 2 N=4 CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis
Candidiasis, Chronic Mucocutaneous
Primary: Clinical Response to Treatment of Mucocutaneous Candidiasis — 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=42 Pembrolizumab + Poly-ICLC in MRP Colon Cancer
Metastatic Colon Cancer · Solid Tumor
Primary: Phase 1: Determine the Maximum Tolerated Dose of Poly-ICLC That Can be Combined With Pembrolizumab — 2 mg
Phase 2 N=23 Study of Plasma Exchange in Severe COVID-19
COVID19
Primary: Number of Participants With Inflammatory Marker Reduction of at Least 50% at Any Efficacy Time Point — 5; 8 Participants — p=0.16
Phase 2 N=24 Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
Pulmonary Hypertension Secondary · Heart Failure
Primary: Mean Pulmonary Artery Pressure (mPAP) During Submaximal Exercise as Compared Between Placebo and Nitrite — 48.75; 48.68; 56.81; 55.0 mmHg — p=0.20
Phase 2 N=388 Varenicline and Bupropion for Alcohol Use Disorder
Alcohol Use Disorder · Alcoholism · Alcohol Dependence
Primary: Alcohol Consumption as Measured by Phosphatidylethanol (PEth) in Blood — -0.406; -0.417; -0.315; 0.250 mikromol/litre
Phase 2 N=212 CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1
Abnormal Glucose Tolerance · Type 1 Diabetes
Primary: Time From Randomization to Confirmed Abnormal Glucose Tolerance Test — 89.2; 71.6 months
Phase 2 N=14 Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
Primary: Objective Response Rate — 0 Participants
Phase 2 N=33 FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC)
Primary: Progression-Free Survival — 14 Participants
Phase 2 N=45 Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration
Small Fiber Neuropathy
Primary: Denervation of Skin — 0.1; 0.1 percent change — p=0.33
Phase 2 N=48 Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
Amyotrophic Lateral Sclerosis (ALS)
Primary: Number of Patients With at Least One Treatment Emergent Adverse Events — 36; 12 Participants
Phase 2 N=17 Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia
Acute Myeloid Leukaemia
Primary: Dose Limiting Toxicity (DLT) (Phase I - Dose Escalation) — 0; 1; 1 Participants
Phase 2 N=107 Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients
Systemic Lupus Erythematosus (SLE)
Primary: Percentage of Participants With SLE Responder Index (SRI)-4 Response Status at Week 29 With Reduced Steroid Dose Maintained Between Weeks 17 and 29 — 15; 3; 8; 6…
Phase 2 N=284 A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants
Hypothyroidism · Thyroid Disease · Euthyroid
Primary: Percentage of Participants With a Sustained TSH Response — 60.76; 75.92 percentage of participants
Phase 2 N=15 Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)
Alcohol Abstinence
Primary: Percentage of Days Abstinent — 74.7; 50.6 percentage of days abstinent — p=<0.03
Phase 2 N=34 An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B
Hemophilia A · Hemophilia B
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 33; 14; 13; 1 Participants